TY - JOUR
T1 - Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis
T2 - A global cohort study
AU - Semenchuk, Julie
AU - Naito, Yumi
AU - Charman, Susan C.
AU - on behalf of the Global CF Registry Collaboration
AU - Carr, Siobhán B.
AU - Cheng, Stephanie Y.
AU - Marshall, Bruce C.
AU - Faro, Albert
AU - Elbert, Alexander
AU - Gutierrez, Hector H.
AU - Goss, Christopher H.
AU - Karadag, Bulent
AU - Burgel, Pierre Régis
AU - Colombo, Carla
AU - Salvatore, Marco
AU - Padoan, Rita
AU - Daneau, Géraldine
AU - Harutyunyan, Satenik
AU - Kashirskaya, Nataliya
AU - Kirwan, Laura
AU - Middleton, Peter G.
AU - Ruseckaite, Rasa
AU - de Monestrol, Isabelle
AU - Naehrlich, Lutz
AU - Mondejar-Lopez, Pedro
AU - Jung, Andreas
AU - van Rens, Jacqui
AU - Bakkeheim, Egil
AU - Orenti, Annalisa
AU - Zomer-van Ommen, Domenique
AU - da Silva-Filho, Luiz Vicente RF
AU - Fernandes, Flavia Fonseca
AU - Zampoli, Marco
AU - Stephenson, Anne L.
AU - Kasmi, Irena
AU - Drali, Ouardia
AU - Burghart, Sabine
AU - Lakatos-Krepcik, Andrea
AU - Eder, Johannes
AU - Jaksch, Peter
AU - Kainz, Katharina
AU - Kallinger, Margit
AU - Leitner, Alexander
AU - Mozdzen, Marta
AU - Pfleger, Andreas
AU - Renner, Sabine
AU - Van Braeckel, Eva
AU - Lucca, Francesca
AU - Altenburg, Josje
AU - Janssens, Hettie
AU - Terheggen, Suzanne
N1 - Publisher Copyright: © 2024
PY - 2024/9
Y1 - 2024/9
N2 - Background: Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF). Methods: This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021. Forced expiratory volume in one second percent predicted (ppFEV1) and body mass index (BMI) twelve months prior to and following a diagnosis of COVID-19 were recorded. Change in mean ppFEV1 and BMI were compared using a t-test. A linear mixed-effects model was used to estimate change over time and to compare the rate of change before and after infection. Results: A total of 6,500 cases of COVID-19 in pwCF from 33 countries were included for analysis. The mean difference in ppFEV1 pre- and post-infection was 1.4 %, (95 % CI 1.1, 1.7). In those not on modulators, the difference in rate of change pre- and post-infection was 1.34 %, (95 % CI -0.88, 3.56) per year (p = 0.24) and -0.74 % (-1.89, 0.41) per year (p = 0.21) for those on elexacaftor/tezacaftor/ivacaftor. No clinically significant change was noted in BMI or BMI percentile before and after COVID-19 infection. Conclusions: No clinically meaningful impact on lung function and BMI trajectory in the year following infection with COVID-19 was identified. This work highlights the ability of the global CF community to unify and address critical issues facing pwCF.
AB - Background: Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF). Methods: This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021. Forced expiratory volume in one second percent predicted (ppFEV1) and body mass index (BMI) twelve months prior to and following a diagnosis of COVID-19 were recorded. Change in mean ppFEV1 and BMI were compared using a t-test. A linear mixed-effects model was used to estimate change over time and to compare the rate of change before and after infection. Results: A total of 6,500 cases of COVID-19 in pwCF from 33 countries were included for analysis. The mean difference in ppFEV1 pre- and post-infection was 1.4 %, (95 % CI 1.1, 1.7). In those not on modulators, the difference in rate of change pre- and post-infection was 1.34 %, (95 % CI -0.88, 3.56) per year (p = 0.24) and -0.74 % (-1.89, 0.41) per year (p = 0.21) for those on elexacaftor/tezacaftor/ivacaftor. No clinically significant change was noted in BMI or BMI percentile before and after COVID-19 infection. Conclusions: No clinically meaningful impact on lung function and BMI trajectory in the year following infection with COVID-19 was identified. This work highlights the ability of the global CF community to unify and address critical issues facing pwCF.
UR - https://www.scopus.com/pages/publications/85202462521
U2 - 10.1016/j.jcf.2024.07.019
DO - 10.1016/j.jcf.2024.07.019
M3 - Article
C2 - 39191560
AN - SCOPUS:85202462521
SN - 1569-1993
VL - 23
SP - 815
EP - 822
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 5
ER -